35 results about "Epidermal Dendritic Cells" patented technology

Provided is a dendritic cell activator that contains, as an active ingredient, a component derived from a natural product which has been eaten for many years and the safety of which has been empirically confirmed, and that is used for inducing or promoting an acquired immune response effective against cancer or infectious disease. Specifically provided are: a dendritic cell activator containing, as an active ingredient, 5-(3,5-dihydroxyphenyl)-y-valerolactone represented by formula (I); and a medicine, a supplement, and a food or beverage each containing the compound represented by formula (I) as an active ingredient. [The configuration of the wavy line may be either R-form or S-form.]

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

The application of the autologous dendritic cell in preparation of the medicine for treating the nerve injury erectile dysfunction can well promote recovery of the erectile function, perform staged reinfusion, induce immune regulation, repair nerve and blood vessel functions and improve a sex hormone regulation pathway. And the autologous dendritic cells are derived from a user, and have the advantages of safety, effectiveness and convenience in use. The combined immune cell therapy is obviously superior to a single treatment path in efficacy, is also more suitable for chronic, non-structural, subclinical and other ED people which are difficult to intervene by traditional methods, and has stronger individual adaptation ability and long-term controllability at the same time. Compared with a traditional scheme, the cell therapy targeting is better, and the treatment effect is faster.

The application discloses a double-targeted glioma composite nanomaterial and a construction method thereof, wherein the composite nanomaterial comprises, from inside to outside, modified mesoporous silica, a drug loading layer, a hybrid membrane layer and a specific modification layer; and the hybrid membrane layer is obtained by combining liposomes and glioma-specific dendritic cell membranes. The double-targeted glioma composite nanomaterial can realize double targeting of glioma cells due to the existence of the hybrid membrane layer and the specific modification layer, has no obvious immunogenicity, can efficiently release preloaded molecules or drugs in cells, and is expected to develop into a new nanomaterial for more effective treatment of glioma.

The invention relates to migration of CCR7-mediated dendritic cell-derived exosomes and improvement of cardiac functions after myocardial infarction, in particular to a dendritic cell-derived exosome, CCR7 expression or activity in the dendritic cell is up-regulated, CCR7 overexpression can enhance migration of the dendritic cell-derived exosomes to the spleen, and CCR7 expression or activity of the dendritic cell-derived exosomes is up-regulated. And the CCR7 knockdown weakens the migration ability of the dendritic cell source exosome.

The invention relates to the technical field of biological medicines and nano medicines, and discloses a co-loaded nano preparation based on a dendritic cell membrane and application of the co-loaded nano preparation. The nano preparation is prepared from hollow mesoporous MnO2, si-CTLA4, PD-1alpha and a DCs hybrid membrane, the preparation is prepared by loading the si-CTLA4 through the hollow mesoporous MnO2, coating the DCs hybrid membrane, and coupling the PD-1alpha through EDC / NHS mediated amidation reaction, so that multi-mechanism synergistic immune activation is realized. In-vitro experiments prove that the nano preparation can efficiently promote T cell proliferation and cancer cell killing; in-vivo experiments show that the nano preparation significantly inhibits LS-related CRC growth and has a good anti-tumor effect. The invention provides a new strategy for improving the immune response rate of ICIs, and also provides a theoretical basis for clinical treatment of LS-related CRC.

The invention relates to a plantain herb acidic polysaccharide PLP-II preparation as well as a preparation method and application thereof. The preparation comprises PLP-II and a lipidosome nano-carrier encapsulating the PLP-II, the lipidosome nano-carrier comprises lipidosome and a gellan derivative connected to the surface of the lipidosome, and the preparation has the effects of specifically targeting dendritic cells in a tumor microenvironment, reducing the off-target effect, enhancing the bioavailability of the PLP-II and improving the drug effect.

The invention belongs to the field of implantable microchips, and particularly relates to a miniature implantable chip for regulating cells to secrete vesicles as well as a preparation method and application of the miniature implantable chip. The miniature implantable chip comprises an implantable device and a wireless power supply device. The implantable device comprises wireless light transmission equipment and hydrogel wrapping the wireless light transmission equipment; the hydrogel comprises dendritic cells and tungsten disulfide quantum dots. The wireless light transmission device is composed of a 3D spiral coil and a miniature printed circuit board. The 3D spiral coil and the micro printed circuit board are packaged in medical grade silica gel; the miniature printed circuit board comprises an integrated radio frequency rectifier and a blue LED chip.

The invention belongs to the technical field of biological medicines, and particularly relates to application of crizotinib in induction of tolerant dendritic cells (tDCs). The invention provides an application of crizotinib in induction of tolerant dendritic cells. It is found that crizotinib can serve as an efficient inducer of tDCs, the activation state of DCs can be remarkably inhibited, the maturation function of DCs can be inhibited, the immune stimulation capacity of DCs can be reduced, then activation of T cells is inhibited, and therefore the crizotinib plays a role in treating immune diseases such as GVHD. In the invention, the inhibition of crizotinib on DCs comprises reduction of expression of maturation indexes CD80, CD40 and CD86. The crizotinib used in the invention is an ALK / ROS1 inhibitor approved by FDA and is mainly used for treating non-small cell lung cancer, the application of the crizotinib in immunotherapy is found, new use of old medicines is realized, and the crizotinib has great economic value.

This invention provides an activatable semiconductor polymer, its preparation method, and its applications. The activatable semiconductor polymer of this invention can efficiently accumulate at tumor sites. Due to the presence of electron-withdrawing groups on its side chains, the polymer's fluorescence is quenched. Upon response to tumor markers—biothiols, reactive oxygen species, and cathepsin B—the polymer's fluorescence recovers, enabling precise imaging and sonodynamic therapy at the tumor site. Simultaneously, the activatable semiconductor polymer of this invention can label immune cells (such as dendritic cells and macrophages) and track their metastasis from the tumor to the draining lymph nodes.

This invention belongs to the field of biomedical technology, specifically relating to the application of crizotinib in inducing tolerant dendritic cells (tDCs). This invention provides the application of crizotinib in inducing tolerant dendritic cells. This invention discovers that crizotinib can act as a highly effective inducer of tDCs, significantly inhibiting the activated state of DCs, suppressing their maturation function, reducing their immunostimulatory capacity, and thus inhibiting T cell activation, thereby exerting a therapeutic effect in immune diseases such as GVHD. The inhibitory effects of crizotinib on DCs in this invention include reducing the expression of maturation markers CD80, CD40, and CD86. The crizotinib used in this invention is an FDA-approved ALK / ROS1 inhibitor, primarily used for the treatment of non-small cell lung cancer. This invention discovers its application in immunotherapy, realizing the repurposing of an existing drug, and has significant economic value.

Provided is a novel gel-type microneedle patch for treating melanoma, which is loaded with dendritic cells (DC) and paclitaxel (PTX). The chemotherapeutic drug paclitaxel utilizes its own toxicity to

Provided is a novel gel-type microneedle patch for treating melanoma, which is loaded with dendritic cells (DC) and paclitaxel (PTX). The chemotherapeutic drug paclitaxel utilizes its own toxicity to kill tumor cells, while the dendritic cells activate an anti-tumor immune response, so that the killing effect on tumors is enhanced, and additionally, the problem that melanoma is prone to recurrence is solved. The provided microneedle patch has good targeting ability and high safety, and can effectively reduce the recurrence rate, thereby achieving painless, non-invasive and precise treatment of melanoma.

The application discloses a kind of biomimetic 3D printing hydrogel scaffold and its preparation method and application, belong to medical instrument technical field.The biomimetic 3D printing hydrogel scaffold includes 3D printing hydrogel scaffold and in 3D printing hydrogel scaffold surface imitating mussel catalytic coating;The biological ink of 3D printing hydrogel scaffold includes methacrylated gelatin, calcium ion pre-crosslinking sodium alginate, dendritic cell-derived exosome loaded with STING agonist and methacrylated modified osteogenic growth peptide;Imitate mussel catalytic coating is by polydopamine layer and the dopa-manganese metal polyphenol network nanoenzyme loaded on the surface of polydopamine layer jointly constitute.By the synergistic effect of each component, effectively solve the technical problem that existing scaffold lacks time sequence treatment mechanism, realize the dual effect of tumor removal and bone defect repair in bone metastasis tumor treatment.

The invention provides a rheumatoid arthritis biomarker as well as a screening method, application and a kit, and the rheumatoid arthritis biomarker is AXL + SIGLEC-6 + dendritic cells (AS DC for short). According to the invention, AS DC can be used as a specific marker for evaluating the disease activity of RA for the first time, and the disease activity of RA can be effectively measured.

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

The invention discloses application of kinsenoside in preparation of drugs for inhibiting metabolic inflammation and improving obesity, kinsenoside regulates and controls an immune system, induces dendritic cells to express immunosuppressive molecules PD-L1 and inhibits costimulatory molecules CD86, so that tolerance of kinsenoside is maintained. The effect further inhibits the activation and infiltration of downstream T cells, and finally reduces the recruitment and activation of macrophages in fat and liver tissues, and breaks the vicious circle of metabolic inflammation. Animal experiments show that the kinsenoside can effectively inhibit weight gain induced by high fat diet and improve abnormal glucose tolerance, insulin resistance, liver lipid deposition and dyslipidemia. The invention discloses the effect of kinsenoside in treating obesity and related complications thereof through a targeted immune metabolic axis for the first time, and provides a new strategy and a candidate compound for developing novel and safe anti-obesity drugs.

A cell culture cartridge is provided that includes a plurality of regions that are geometrically configured to provide fluid flow symmetrical to each of the plurality of regions to avoid flow dead zones within each of the plurality of regions. In some embodiments, at least eight inlets are provided, where the inlets are located at each corner of the cell culture cassette. In some embodiments, the shared outlet is located on the top surface of the cell culture cartridge.

Flt3L is a soluble, focused signal that can expand the dendritic cell compartment. The disclosure provides for methods for regenerating tissue, for preventing wound formation, or for treating wounds in a subject. The methods are achieved by administering a composition comprising a fms related tyrosine kinase 3 ligand (Flt3L) polypeptide to the subject.

To provide a dendritic cell generating apparatus and method.SOLUTION: A cell culture cartridge comprises a plurality of zones geometrically configured to provide a symmetrical fluid flow with each of the plurality of zones to avoid dead areas in a flow within each of the plurality of zones. In certain embodiments, at least eight inlets are provided, with an inlet positioned at each corner of the cell culture cartridge. In certain embodiments, a shared outlet is positioned on a top surface of the cell culture cartridge. The present invention provides an optimal and further efficient approach to automated generation of dendritic cells (DCs).SELECTED DRAWING: None

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, such as lipid nanoparticles (LNPs), for targeted delivery to tissues or cell types. The compounds and formulations provided herein are designed to have a targeting moiety configured to provide selective delivery characteristics for the formulation, and a lipid tail for incorporation into a bilayer membrane of the formed lipid nanoparticles.

The subject invention relates to a novel compound and method for treating cancer in a subject using photodynamic therapy (PDT). The novel compound comprises zinc(II) phthalocyanine substituted with two or four nitric oxide (NO)-releasing moieties that release NO upon interaction with the intracellular glutathione, which reduces the cellular oxygen consumption rate, thus relieving the hypoxic status of cancer cells. Upon light irradiation, the novel compound generates reactive oxygen species (ROS), induces cytotoxicity under a hypoxic condition, overcoming the oxygen-dependent nature of PDT, and elicits the release of damage-associated molecular patterns, inducing the maturation of dendritic cells and triggering an antitumor immune response.

Provided is a novel gel-type microneedle patch for treating melanoma, which is loaded with dendritic cells (DC) and paclitaxel (PTX). The chemotherapeutic drug paclitaxel utilizes its own toxicity to kill tumor cells, while the dendritic cells activate an anti-tumor immune response, so that the killing effect on tumors is enhanced, and additionally, the problem that melanoma is prone to recurrence is solved. The provided microneedle patch has good targeting ability and high safety, and can effectively reduce the recurrence rate, thereby achieving painless, non-invasive and precise treatment of melanoma.

The invention relates to a pharmaceutical composition for treating pancreatic cancer. The present invention relates to a method for treating pancreatic cancer comprising administering to a patient in need thereof a CD40 agonist in combination with dendritic cells loaded with mesothelioma cell lysates. Another aspect of the invention relates to dendritic cells loaded with mesothelioma cell lysates for use in the treatment of pancreatic cancer. A last aspect of the invention relates to a pharmaceutical composition comprising such loaded dendritic cells.

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

Provided herein are methods relating to administering a dendritic cell activating therapy as an adjunct to radiation therapy or an energy-based therapy for treating a tumor or cancer in an individual.

The invention belongs to the technical field of preparation of immune activators, and particularly relates to a preparation method of an autoimmune activator. The invention provides a preparation method of an autoimmune activator, which comprises the following steps: separating an albuginea layer from peripheral blood, then respectively preparing an autoimmune exosome and an autovariant cell immune antigen through the steps of resuspension counting, water bath heating, programmed cooling, unfreezing centrifugation and the like, and mixing, freezing and drying to obtain the autoimmune activator. The technical scheme is simple and convenient, the obtained autoimmune activator is high in activity, and after subcutaneous injection, the autoimmune activator can effectively activate subcutaneous Langerhans cells, dendritic cells and the like, enhance the recognition ability of DC cells on antigens, induce Langerhans cells / DC cells to activate Th cells, enhance the effect of effector T cells and remove in-vivo variant cells, so that the autoimmune activator has a good immunogenicity. Therefore, autoimmune diseases or other health problems with immune imbalance states are improved, and the composition is safe and free of side effects.